{
  "meta": {
    "timestamp": "2025-01-06T14:07:11.252147",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Mind Medicine (MindMed) Inc",
      "symbol": "MNMD",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Regulatory hurdles and uncertain FDA approval timelines",
            "High market volatility and speculative stock performance",
            "Financial sustainability concerns due to high cash burn rate",
            "Intense competition in the psychedelic medicine space",
            "Ethical and safety debates surrounding psychedelic therapies"
          ],
          "controversies": [
            "Public perception and scientific acceptance of psychedelic treatments",
            "Potential delays in clinical trials or regulatory approvals"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Ethical concerns regarding the use of psychedelics in medical treatments"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "MindMed Receives FDA Breakthrough Therapy Designation and Announces ...",
              "snippet": "NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the \"Company\" or \"MindMed\"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809663+00:00",
              "published_date": null,
              "source_hash": "7201314da6269fe5b5888678c3e53728"
            },
            {
              "url": "",
              "title": "MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM ...",
              "snippet": "NEW YORK - May 25, 2023 \u2014 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the \"Company\" or \"MindMed\"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the Company has published a report by Greenleaf Health, Inc. (\"Greenleaf\") setting ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809769+00:00",
              "published_date": null,
              "source_hash": "5ab79b4ae220314aae59851710d34977"
            },
            {
              "url": "",
              "title": "Rethinking Brain Health | MindMed",
              "snippet": "MindMed works to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology. MindMed discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236814+00:00",
              "published_date": null,
              "source_hash": "6cf60d88c1fbcadc3efa114aadc27c16"
            },
            {
              "url": "",
              "title": "MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 ...",
              "snippet": "NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809799+00:00",
              "published_date": null,
              "source_hash": "36f8fc8ac593427b010339a3e299a1ae"
            },
            {
              "url": "",
              "title": "MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for ...",
              "snippet": "Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809809+00:00",
              "published_date": null,
              "source_hash": "18eb244e7e866033f10e1dca1b2abeb3"
            },
            {
              "url": "",
              "title": "MindMed Announces Business Update and Anticipated Milestones for 2024",
              "snippet": "NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the \"Company\" or \"MindMed\"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2024. ... We will be working closely with the FDA to finalize our ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809820+00:00",
              "published_date": null,
              "source_hash": "5ac03abe94b75c7a635c998da21e0013"
            },
            {
              "url": "",
              "title": "FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety ...",
              "snippet": "- FDA clearance leads to first commercial IND for LSD, enabling initiation of Phase 2b dose-optimization trial of MM-120 in early 2022 - NEW YORK, January 25, 2022 \u2014 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the \"Company\"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809829+00:00",
              "published_date": null,
              "source_hash": "2e01b0b74150f8b759377eb355a15d0f"
            },
            {
              "url": "",
              "title": "FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety ...",
              "snippet": "NEW YORK, Jan. 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the \"Company\"), a clinical-stage biopharmaceutical company developing psychedelic ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809840+00:00",
              "published_date": null,
              "source_hash": "980f73665f5f2c1ee2a9d6e1ef95afc8"
            },
            {
              "url": "",
              "title": "Mind Medicine: Two Pathways Created From One Pipeline Clinical ...",
              "snippet": "Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. ... risks related to trial outcomes and regulatory ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809848+00:00",
              "published_date": null,
              "source_hash": "44fc01c00fd2b6e4afdcab3276d575d5"
            },
            {
              "url": "",
              "title": "What's Going On With MindMed And Psychedelic Stocks?",
              "snippet": "Mind Medicine (MindMed) Inc. MNMD shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:42.809857+00:00",
              "published_date": null,
              "source_hash": "e9baf142ad72cc61af29ffbe528d1b4a"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) Inc. (MNMD)",
              "snippet": "NEW YORK, November 18, 2024--Mind ... s regulatory and quality functions, as well as its product registration strategies. NEW YORK, November 13, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:46.288133+00:00",
              "published_date": "2025-01-04T00:00:00+00:00",
              "source_hash": "46db10a752090040e21d7b759e5d29a3"
            },
            {
              "url": "",
              "title": "MindMed Stock Skyrockets 94% Year to Date: What's Driving It?",
              "snippet": "MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD).",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:56.557303+00:00",
              "published_date": "2024-12-24T16:40:00+00:00",
              "source_hash": "7d0da6c78342294c0e86f5604bd887c4"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $27.71 Consensus Price Target from Brokerages",
              "snippet": "Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) has earned an average recommendation of \"Buy\" from the eleven research firms that are covering the firm, MarketBeat.com reports.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:46.288271+00:00",
              "published_date": "2024-12-19T00:00:00+00:00",
              "source_hash": "2bb838e92d883e874796e5586c282812"
            },
            {
              "url": "",
              "title": "Geode Capital Management LLC Has $9.55 Million Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)",
              "snippet": "Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) by 10.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:46.288299+00:00",
              "published_date": "2025-01-02T00:00:00+00:00",
              "source_hash": "93520564f1d31ec4493ed6288ac0a283"
            },
            {
              "url": "",
              "title": "MindMed to Be Added to the Nasdaq Biotechnology Index",
              "snippet": "NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T21:06:46.288322+00:00",
              "published_date": "2024-12-19T07:00:00+00:00",
              "source_hash": "2ba6bbdb6759d8ef21132c3f8a357942"
            },
            {
              "url": "",
              "title": "Governance Documents :: Mind Medicine (MindMed) Inc. (MNMD)",
              "snippet": "Download Nominating and Corporate Governance Committee Charter. Code of Conduct and Ethics. Download Code of Conduct and Ethics",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236917+00:00",
              "published_date": null,
              "source_hash": "dafb764892c5632defdd46fe36d8629e"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) Inc. (MNMD)",
              "snippet": "Headquarters. Mind Medicine (MindMed) Inc. One World Trade Center Suite 8500 New York, NY 10007 United States",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820495+00:00",
              "published_date": null,
              "source_hash": "54efaf5be624c86c3c11e26808e69b4f"
            },
            {
              "url": "",
              "title": " Mind Medicine, Inc.",
              "snippet": "Mind Medicine, Inc. Notes to Consolidated Financial Statements (Expressed in United States Dollars) For the period May 30, 2019 (date of incorporation) to December 31, 2019 5 1. NATURE OF OPERATIONS AND GOING CONCERN Mind Medicine, Inc. (the \"Company\" or \"MindMed\") was incorporated under the laws of the state of",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236941+00:00",
              "published_date": null,
              "source_hash": "edbb72a00c652697735519bb975b2445"
            },
            {
              "url": "",
              "title": " Mind Medicine (MindMed) Inc.",
              "snippet": "Mind Medicine (MindMed) Inc. (Formerly Broadway Gold Mining Ltd.) Notes to Consolidated Financial Statements (Expressed in thousands of United States Dollars) For the Year Ended December 31, 2020 5 1. NATURE OF OPERATIONS Mind Medicine (MindMed) Inc. (formerly Broadway Gold Mining Ltd.) (the \"Company\" or \"MindMed\")",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236951+00:00",
              "published_date": null,
              "source_hash": "1b9ecd0eb51f41d957d83bc4f84c7361"
            },
            {
              "url": "",
              "title": "About :: Mind Medicine (MindMed) Inc. (MNMD)",
              "snippet": "MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236960+00:00",
              "published_date": null,
              "source_hash": "4683bc7bd29d5c6ed144427154f163ec"
            },
            {
              "url": "",
              "title": "What's Going On With MindMed And Psychedelic Stocks?",
              "snippet": "Mind Medicine (MindMed) Inc. MNMD shares are trading lower ... expressed concerns about the designs of the ... issues faced by companies developing psychedelic therapies and treatments.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236972+00:00",
              "published_date": null,
              "source_hash": "014d6ae2c8babbcb4fdcdf5f3a1137d0"
            },
            {
              "url": "",
              "title": "MindMed Inc. - Wikipedia",
              "snippet": "MindMed was founded in May 2019 by Jamon Rahn, a Y-Combinator alumnus who worked at Uber, and Stephen Hurst, a 35-year veteran of the pharmaceutical industry.Rahn, who was interested in the Silicon Valley trend of psychedelic microdosing to improve focus after struggling with his own mental health and addiction issues, spent two years researching the therapeutic potential of psychedelics prior ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236982+00:00",
              "published_date": null,
              "source_hash": "cf465615419fb3703416e73b74e8aed0"
            },
            {
              "url": "",
              "title": "MindMed Closes Acquisition of HealthMode, a Leading Machine Learning ...",
              "snippet": "NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF, DE: MMQ) (\"MindMed\"), a leading psychedelic medicine biotech company, is pleased to announce that it ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.236992+00:00",
              "published_date": null,
              "source_hash": "f1fc9a3c78c79dd4b1653d2b05ca2f48"
            },
            {
              "url": "",
              "title": " Rethinking Brain Health | MindMed",
              "snippet": "MindMed MIND MEDICINE (MINDMED) INC. CODE OF BUSINESS CONDUCT AND ETHICS Doc. No. BCG-OOI Rev. No. Effective: 01/01/2022 CODE OF BUSINESS CONDUCT AND ETHICS Mind Medicine (MindMed) Inc. (the \"Company\") is committed to creating an environment where we are able to do our best work while maintaining the highest standards of business conduct and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:48.237002+00:00",
              "published_date": null,
              "source_hash": "eb6abdd80cf814518dee60f1ce02cd5d"
            },
            {
              "url": "",
              "title": "Geode Capital Management LLC Has $9.55 Million Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)",
              "snippet": "Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) by 10.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:56.557281+00:00",
              "published_date": "2025-01-02T07:26:00+00:00",
              "source_hash": "c812b13ade8d3fdb031d3e691e95629c"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 8.5% After Insider Selling",
              "snippet": "Inc. (NASDAQ:MNMD - Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded as low as $6.98 and last traded at $6.98. Approximately 534,967 shares changed hands during trading,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:50.316628+00:00",
              "published_date": "2024-12-29T08:43:00+00:00",
              "source_hash": "abca167fbaa8ba945f3935a4d0ae6e33"
            },
            {
              "url": "",
              "title": "Mind Medicine to be added to Nasdaq Biotechnology Index December 23.",
              "snippet": "Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23. \"2024 has been a transformational year for MindMed.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:50.316648+00:00",
              "published_date": "2024-12-19T12:25:00+00:00",
              "source_hash": "ea8e09aac991fb5555816d9fea1aded9"
            },
            {
              "url": "",
              "title": "MindMed to Be Added to the Nasdaq Biotechnology Index",
              "snippet": "Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the \"Company\" or \"MindMed\"), a ... Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "retrieved_at": "2025-01-06T21:06:50.316657+00:00",
              "published_date": "2024-12-19T00:00:00+00:00",
              "source_hash": "2927bc4adc56a9b66badd71b4856cda1"
            },
            {
              "url": "",
              "title": "MindMed Reports First Quarter 2024 Financial Results and Business ...",
              "snippet": "NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the \"Company\" or \"MindMed\"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update. ... (R&D). R&D expenses ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820423+00:00",
              "published_date": null,
              "source_hash": "98c9e0fbe04e36109029a4c8579c38d2"
            },
            {
              "url": "",
              "title": "MindMed Reports Third Quarter 2024 Financial Results and Business ...",
              "snippet": "NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820482+00:00",
              "published_date": null,
              "source_hash": "e08702b4abf9c8c0796bdd5fc401c9e2"
            },
            {
              "url": "",
              "title": "MindMed Reports Full Year 2022 Financial Results and Business ...",
              "snippet": "NEW YORK, March 9, 2023 \u2014 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), ... (R&D). R&D expenses were $36.2 million for the year ended December 31, 2022, compared to $34.8 million for the year ended December 31, 2021, an increase of $1.4 million. ... MindMed Reports Third Quarter 2023 Financial Results and Business Highlights ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820504+00:00",
              "published_date": null,
              "source_hash": "6ec23ab54ad0b92e24341a376496095b"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) Inc. (MNMD) - Yahoo Finance",
              "snippet": "Get the detailed quarterly/annual income statement for Mind Medicine (MindMed) Inc. (MNMD). Find out the revenue, expenses and profit or loss over the last fiscal year.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820517+00:00",
              "published_date": null,
              "source_hash": "576893ea3d4e3919865d2f1faa4420f1"
            },
            {
              "url": "",
              "title": " Mind Medicine (MindMed) Inc.",
              "snippet": "Mind Medicine (MindMed) Inc. Condensed Consolidated Interim Financial Statements (Expressed in Thousands of United States Dollars) For The Three and Six Months Ended June 30, 2021 and June 30, 2020 ... issuance costs (Note 7) 24,953,850 - 7,554 199 - - - 7,752 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820526+00:00",
              "published_date": null,
              "source_hash": "f1fe1004389991c22703d1d653b94206"
            },
            {
              "url": "",
              "title": "Annual Reports :: Mind Medicine (MindMed) Inc. (MNMD)",
              "snippet": "SEC Filings . SEC Filings. Overview; All SEC Filings; Annual Reports; Filing Type:",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820536+00:00",
              "published_date": null,
              "source_hash": "8cbd8d011f133b4921c6046e566aabac"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) Inc. (MNMD) Valuation Measures & Financial ...",
              "snippet": "Find out all the key statistics for Mind Medicine (MindMed) Inc. (MNMD), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820545+00:00",
              "published_date": null,
              "source_hash": "a93418ebe9fa480603b43ecedf102773"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) Inc. (MMED.NE) - Yahoo Finance",
              "snippet": "Find out all the key statistics for Mind Medicine (MindMed) Inc. (MMED.NE), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820554+00:00",
              "published_date": null,
              "source_hash": "d488d6e2e9fce6dea66c1d26a4f3fef6"
            },
            {
              "url": "",
              "title": "MindMed Stock Skyrockets 94% Year to Date: What's Driving It? - TradingView",
              "snippet": "Mind Medicine (MindMed) Inc. Price and Consensus. Mind Medicine (MindMed) Inc. price-consensus-chart | Mind Medicine (MindMed) Inc. Quote. In the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents per share. Loss per share estimates for 2025 have narrowed from $2.15 to $1. ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:53.820562+00:00",
              "published_date": null,
              "source_hash": "adfd292f2a95f1f00ca884a08a15b2e6"
            },
            {
              "url": "",
              "title": "Mind Medicine (MindMed) Inc. (MNMD)",
              "snippet": "today announced its financial results for the quarter ended September 30, 2024, and provided a business update. NEW YORK, October 24, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:56.557204+00:00",
              "published_date": "2025-01-04T00:00:00+00:00",
              "source_hash": "f23a3d705c5e22a7948e14e706d65c49"
            },
            {
              "url": "",
              "title": "Mind Medicine Inc Ordinary Shares MNMD",
              "snippet": "We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:56.557294+00:00",
              "published_date": "2025-01-03T13:00:00+00:00",
              "source_hash": "f922fa031d10034b10c3e78062540f56"
            },
            {
              "url": "",
              "title": "MindMed Announces New Employee Inducement Grants",
              "snippet": "NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mind Medicine (MindMed) Inc Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "retrieved_at": "2025-01-06T21:06:56.557312+00:00",
              "published_date": "2024-12-02T07:00:00+00:00",
              "source_hash": "29e1c4652b303a0ca873c50f8fc4a374"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Mind Medicine (MindMed) Inc regulatory challenges FDA",
              "rationale": "Investigate regulatory hurdles and legal issues with FDA approvals for psychedelic-based therapies",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "Mind Medicine (MindMed) Inc ethical concerns psychedelic treatments",
              "rationale": "Explore public and scientific debates on the ethical implications of using psychedelics in medical treatments",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "Mind Medicine (MindMed) Inc financial sustainability R&D costs",
              "rationale": "Assess the company's financial stability and cash burn rate due to extensive R&D efforts",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:07:11.252154",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}